OncoMatch/Clinical Trials/NCT07444814
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Is NCT07444814 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies HWK-007 for endometrial cancer.
Treatment: HWK-007 — HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Ovarian Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
Disease stage
Metastatic disease required
Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent
Lab requirements
Cardiac function
Significant cardiovascular disease; QTcF ≥ 470 ms
Significant cardiovascular disease; Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arkansas · Little Rock, Arkansas
- UCLA - Hematology/Oncology Clinical Research Unit · Los Angeles, California
- St. Francis Medical Center (OSF Healthcare) · Peoria, Illinois
- START - Midwest · Grand Rapids, Michigan
- Hackensack University Medical Center - John Theurer Cancer Center · Hackensack, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify